Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Plus Therapeutics Has Completed Dosing In Cohort 5 Of ReSPECT-LM Phase 1 Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases From Solid Tumors; Company Expects Moving Into Cohort 6 In Q2 2024 Following Standard Safety Review

Author: Benzinga Newsdesk | March 11, 2024 07:21am

Posted In: PSTV